N@N

Steve Valiquette Maintained (THC) at Buy with Increased Target to $70 on, Feb 14th, 2023

Steve Valiquette of Barclays, Maintained "Tenet Healthcare Corporation" (THC) at Buy with Increased Target from $67 to $70 on, Feb 14th, 2023.

Steve has made no other calls on THC in the last 4 months.

There are 11 other peers that have a rating on THC. Out of the 11 peers that are also analyzing THC, 1 agrees with Steve's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Scott Fidel of "Stephens & Co." Maintained at Hold with Increased Target to $60 on, Friday, February 10th, 2023

These are the ratings of the 10 analyists that currently disagree with Steve

---

• Ann Hynes of "Mizuho" Reiterated at Strong Buy and Held Target at $60 on, Friday, February 10th, 2023
• Ben Hendrix of "RBC Capital" Maintained at Buy with Increased Target to $73 on, Friday, February 10th, 2023
• David Macdonald of "Truist Securities" Maintained at Strong Buy with Increased Target to $66 on, Friday, February 10th, 2023
• Pito Chickering of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $65 on, Friday, February 10th, 2023
• Stephen Baxter of "Wells Fargo" Maintained at Buy with Increased Target to $59 on, Tuesday, January 3rd, 2023
• Jamie Perse of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $80 on, Tuesday, November 1st, 2022
• John Ransom of "Raymond James" Maintained at Strong Buy with Decreased Target to $80 on, Thursday, October 27th, 2022
• Jason Cassorla of "Citigroup" Maintained at Strong Buy with Decreased Target to $76 on, Tuesday, October 25th, 2022
• Whit Mayo of "SVB Leerink" Maintained at Buy with Decreased Target to $55 on, Tuesday, October 25th, 2022
• Sarah James of "Barclays" Maintained at Buy with Decreased Target to $67 on, Monday, October 24th, 2022

Contributing Sources

---